Traumatic Brain Injury (TBI): Moderate/Severe

ALGORITHM 1: Post-Resuscitation

Inclusion Criteria:
- Patient with traumatic brain injury and Glasgow Coma Scale (GCS) less than or equal to 12

Exclusion Criteria:
- Patients found down without clear traumatic brain injury (TBI) (Can be used in conjunction with Post Cardiac Arrest Pathway if considered beneficial)

Emergency Department Management
- Trauma and Neurosurgery Consult
- Head Computed Tomography (CT) scan - if not already obtained (STAT upload) or a quick MRI as a viable (radiation-free) option
- 2 IVs with Normal Saline (NS) as maintenance
- Modified Rapid sequence intubation (RSI) if not already performed

For patients with signs of elevated intracranial pressure (ICP) empirically treat:
- 3% (0.5 mEq/mL Na+) Hypertonic saline (HTS) bolus 5mL/kg/dose via peripheral IV or central line
- For patients with ongoing seizures use the status epilepticus clinical pathway (below).
- For patients with severe TBI who have not received a dose of levetiracetam at another institution, give levetiracetam 20mg/kg IV (max 2 grams)
- If transporting to Operating Room: Consider mild hyperventilation to PCO$_2$ of 32-35 mmHg

**Standard Neuroprotective Measures:**
- Head of bed at 30°, midline
- Non-restrictive cervical collar
- Sodium greater than 140 mmol/L
- Normothermia 36.8 °C
- Oxygen Saturation 93%-97%
- PCO$_2$ 35-40 mmHg
- Normoglycemia 80-180 mg/dL
- Levetiracetam 10mg/kg/dose BID x 7 days (Max dose 1,000mg BID)
- Appropriate sedation

Rehab Considerations for Severe TBI Patients
- Consult Physical Medicine & Rehabilitation (PM&R) for patients that have stabilized or have been hospitalized greater than 5 days
- Consult PT/OT within 48 hours of admission for early passive range of motion, bracing & splinting, and out of bed when appropriate
- Consult speech therapy when patient stabilized or have been hospitalized for greater than 5 days
- Anschutz: Consult rehab neuropsychology when PM&R is consulted

*Post Cardiac Arrest Clinical Pathway
*Status Epilepticus Clinical Pathway
Algorithm 2. Moderate/Severe Traumatic Brain Injury (TBI) Intracranial Pressure (ICP) Management

**Neuroprotective Monitoring:**
- End Tidal CO2 (ETCO2), core temperature
- If needed, central access and arterial line
- Intracranial pressure (ICP) monitor or external ventricular drain (EVD) placed if needed per neurosurgery in emergency department, operating room, or PICU
- Continuous EEG (cEEG) when stabilized

**ICP Management Algorithm:**

**Inclusion Criteria:**
- Patients with Moderate/Severe TBI with an ICP monitor in place

**Exclusion Criteria:**
- Patient without an ICP monitor in place

**Cerebral Spinal Fluid (CSF) Drainage:**

- Standard Neuroprotective Measures:
  - Head of bed at 30°, midline
  - Non-restrictive cervical-collar
  - sodium greater than 140 mmol/L
  - Normothermia 36.8 °C
  - O2 Sat 93%-97%
  - PCO2 35-40 mmHg
  - Normoglycemia 80-180 mg/dL
  - Levetiracetam 10mg/kg BID x 7 days (Max dose 1,000mg BID)

- **Hyperosmolar Therapy**
  - Bolus hypertonic saline (HTS) if sodium less than 165 mmol/L.
  - If fluid overloaded or not responsive to HTS, bolus mannitol 0.5g/kg/dose if osmolality (Osm) less than 340 MOSM/Kg. Can Repeat after 15 minutes if ICP is elevated.

- **Neuroprotective monitoring including ICP:**
  - Maintain cerebral perfusion pressure (CPP) and euvolemia
  - If euvoletic, use ionotropic/vasoactive support

- **Comfort Sedation**
  - Richmond Agitation and Sedation Score (RASS) less than or equal to -1
  - Comfort score 17-24
  - With a goal of preserving a neurologic exam and safety for the patient

- **Deep Sedation**
  - Midazolam, fentanyl, or morphine
  - Avoid hypotension
  - Consider neuromuscular blockade if not ventilating or for refractory ICP

- **Hyperosmolar Therapy**
  - Hyperosmolar saline (HTS) is first line in patient with central venous line and not fluid overloaded
  - 3% HTS may be administered via peripheral IV in emergent situations
  - 12% (2mL;kg; Max=60mL) and 23.4% (1mL;kg; max=30mL) boluses via central venous line for fluid overloaded patients
  - Mannitol 0.5-1g/kg/dose IV if HTS not available or refractory to HTS
  - Monitor sodium and osmolality (Osm) every 4 hours
  - Sodium less than 165 mmol/L and osmolality less than 340 MOSM/Kg

**Standard Neuroprotective Measures:**
- For patients with external ventricular drain (EVD) in place?

**Fluid Goals and Vasoactives**
- Maintain cerebral perfusion pressure (CPP) and euvoletic
- If euvoletic, use ionotropic/vasoactive support

**ICP Parameters**
- Start deep sedation with goal State Behavioral Scale (SBS) equal to -3
- Notify neurosurgery (NSYG), trauma and Neurology critical care (NCC) Neuromuscular Blockade Consider Repeat CT Scan

**External Ventricular Drain (EVD) in place?**

- Elevated ICP?
  - Hyperosmolar Therapy
  - Maximize external ventricular drain (EVD) drainage and hyperosmolar therapy. Discuss with Neurology if ICP remains reactive, if so could consider further sedation.

- Elevated ICP?
  - Neuroprotective monitoring including ICP

- Comfort Sedation
  - Richmond Agitation and Sedation Score (RASS) less than or equal to -1
  - Comfort score 17-24
  - With a goal of preserving a neurologic exam and safety for the patient

- Deep Sedation
  - Midazolam, fentanyl, or morphine
  - Avoid hypotension
  - Consider neuromuscular blockade if not ventilating or for refractory ICP

- Hyperosmolar Therapy
  - Hyperosmolar saline (HTS) is first line in patient with central venous line and not fluid overloaded
  - 3% HTS may be administered via peripheral IV in emergent situations
  - 12% (2mL;kg; Max=60mL) and 23.4% (1mL;kg; max=30mL) boluses via central venous line for fluid overloaded patients
  - Mannitol 0.5-1g/kg/dose IV if HTS not available or refractory to HTS
  - Monitor sodium and osmolality (Osm) every 4 hours
  - Sodium less than 165 mmol/L and osmolality less than 340 MOSM/Kg

**Comfort Sedation**
- Richmond Agitation and Sedation Score (RASS) less than or equal to -1
- Comfort score 17-24
- With a goal of preserving a neurologic exam and safety for the patient

**Deep Sedation**
- Midazolam, fentanyl, or morphine
- Avoid hypotension
- Consider neuromuscular blockade if not ventilating or for refractory ICP

**Hyperosmolar Therapy**
- Hyperosmolar saline (HTS) is first line in patient with central venous line and not fluid overloaded
- 3% HTS may be administered via peripheral IV in emergent situations
- 12% (2mL;kg; Max=60mL) and 23.4% (1mL;kg; max=30mL) boluses via central venous line for fluid overloaded patients
- Mannitol 0.5-1g/kg/dose IV if HTS not available or refractory to HTS
- Monitor sodium and osmolality (Osm) every 4 hours
- Sodium less than 165 mmol/L and osmolality less than 340 MOSM/Kg

**Comfort Sedation**
- Richmond Agitation and Sedation Score (RASS) less than or equal to -1
- Comfort score 17-24
- With a goal of preserving a neurologic exam and safety for the patient

**Deep Sedation**
- Midazolam, fentanyl, or morphine
- Avoid hypotension
- Consider neuromuscular blockade if not ventilating or for refractory ICP

**Hyperosmolar Therapy**
- Hyperosmolar saline (HTS) is first line in patient with central venous line and not fluid overloaded
- 3% HTS may be administered via peripheral IV in emergent situations
- 12% (2mL;kg; Max=60mL) and 23.4% (1mL;kg; max=30mL) boluses via central venous line for fluid overloaded patients
- Mannitol 0.5-1g/kg/dose IV if HTS not available or refractory to HTS
- Monitor sodium and osmolality (Osm) every 4 hours
- Sodium less than 165 mmol/L and osmolality less than 340 MOSM/Kg

**Comfort Sedation**
- Richmond Agitation and Sedation Score (RASS) less than or equal to -1
- Comfort score 17-24
- With a goal of preserving a neurologic exam and safety for the patient

**Deep Sedation**
- Midazolam, fentanyl, or morphine
- Avoid hypotension
- Consider neuromuscular blockade if not ventilating or for refractory ICP

**Hyperosmolar Therapy**
- Hyperosmolar saline (HTS) is first line in patient with central venous line and not fluid overloaded
- 3% HTS may be administered via peripheral IV in emergent situations
- 12% (2mL;kg; Max=60mL) and 23.4% (1mL;kg; max=30mL) boluses via central venous line for fluid overloaded patients
- Mannitol 0.5-1g/kg/dose IV if HTS not available or refractory to HTS
- Monitor sodium and osmolality (Osm) every 4 hours
- Sodium less than 165 mmol/L and osmolality less than 340 MOSM/Kg
TARGET POPULATION

Inclusion Criteria

- All patients cared for at Children’s Hospital Colorado with known or suspected brain injury secondary to trauma with a post-resuscitation Glasgow Coma Score (GCS) of less than 8 (Severe Traumatic Brain Injury) or GCS 9-12 (Moderate Traumatic Brain Injury) with concern for potential decompensation. This includes patients less than 2 years of age with concern for abusive head trauma.

Exclusion Criteria

- Patient found down without clear trauma

BACKGROUND | DEFINITIONS

This protocol is based on “The Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents” and on the existing literature and is intended to provide standardization in the care of traumatic brain injury (TBI) patients at Children’s Hospital Colorado.

Scope: Children’s Hospital Colorado – Anschutz Medical Campus (CHCO-Anschutz)

Severe Traumatic Brain Injury: Glasgow Coma Score (GCS) of 3 – 8

Moderate TBI: GCS of 9-12

Mild TBI: GCS of 13-15
INITIAL EVALUATION & CLINICAL MANAGEMENT

Emergency Department Management:

- Obtaining the best neurologic exam safely is critical for neurosurgical decision-making and appropriate patient management. In all patients, Glasgow Coma Scale (GCS) is assessed. When possible, consider avoiding further sedatives and paralytics until neurosurgery resident or fellow examines patient. Call neurosurgery early when sedation or intubation may be necessary.

- When sedation or analgesia are necessary, use short acting intermittent agents, including fentanyl (1-2 mcg/kg) and/or ketamine 0.5-1 mg/kg IV. Note that Propofol is not appropriate for long-term sedation in children, but is a reasonable option for the first hours. Midazolam may also be used, but can alter the neurologic exam for hours.

Primary Survey

- Airway control
  - Intubate for GCS of eight (8) or less or if unable to maintain stable airway.
  - Use rapid sequence intubation (RSI) Trauma Guideline
  - Assess GCS prior to administering sedation.
  - Maintain head of patient in neutral position, use rigid cervical collar (e.g. Aspen collar).

- Breathing
  - Maintain oxygen saturations at 93-97%
  - Maintain PCO₂ 35-40 mmHg
  - Monitor end tidal CO₂ (ETCO₂) and obtain blood gases to correlate ETCO₂ to PCO₂ when indicated.

- Circulation
  - See Table 1 for minimum acceptable blood pressure by age group.
  - Avoid hypotension by ensuring adequate circulating blood volume using isotonic fluid (Normal Saline) or Trauma Packed red blood cell (PRBC) units as indicated.
  - Avoid hypotonic fluids as they exacerbate brain swelling.
  - May use pressor support once intravascular volume has been repleted.
  - Once euvoelemia is attained, use Normal Saline (avoid hypotonic fluids) at age-appropriate maintenance intravenous (IV) rate.

Secondary Survey:

- Full neurologic exam including cranial nerve exam
- Trauma labs and x-rays per protocol, including electrolytes, glucose, ionized calcium, full CBC, and PT/PTT
- Obtain head computed tomography (CT) and other indicated imaging. STAT upload prior imaging if available
- If head of bed elevation is preferred, utilize reverse Trendelenburg (Revere T) positioning rather than just raising the head of the bed until thoracic spine cleared. Place Foley and orogastric tube (OG) unless contraindicated. Establish adequate IV access. Obtain CVL when indicated.

Neuroprotective Measures

Glucose Management

See Glycemic Guidelines: Critical Care for Patients 6 Months of Age and Older or Glycemic Guidelines: Critical Care for Patients Less than 6 Months of Age

- Check serum glucose measurements on admission to PICU and minimum every 6 hours for first 48 hours
Maintain serum blood glucose 80-180 mg/dL. Persistent hyperglycemia (greater than 180 mg/dL) and severe hypoglycemia (less than 40 mg/dL) are associated with increased mortality/worse neurological outcome.

Avoid bolus insulin dose in trauma patients.

**Ventilation**
- Goal PCO₂ of 35-40 mmHg
- Monitor end-tidal CO₂ (ETCO₂).
- Obtain blood gases to correlate ETCO₂ with PCO₂ as indicated.
- Aggressive, rapid hyperventilation must be reserved for acute ICP crisis as adjunct with therapy escalation. Effect is temporary (less than 30 min), and rebound ICP elevation will occur with normalization of CO₂.

**Seizures**
- Seizure prophylaxis with levetiracetam 10 mg/kg BID x 7 days (max dose 1 g BID) should be administered to all severe TBI patients of all ages.
- Seizure monitoring:
  - Initiate EEG as early as feasible to evaluate for subclinical seizures, encephalopathy and reactivity. Seizures are common in patients with TBI.
  - For all patients with TBI admitted to the PICU, monitor with EEG for a minimum of 24 hours, or longer if clinically indicated.
    - Infants and patients with suspected abusive head trauma have a high risk for seizures and may benefit from prolonged monitoring of 48-72 hours.
    - GCS is an unreliable marker of the risk for seizures in children less than 2 years of age.
  - If the patient develops seizures, discuss treatment options with the Neurocritical Care Consult team at Anschutz or the Neurology team at Colorado Springs. Reference the Status Epilepticus Clinical Pathway as needed.

**Sedation/Analgesia**
- Provide analgesia and sedation to achieve a COMFORT Pain Score of 17-24 and a Richmond Agitation and Sedation Score (RASS) of -1, unless deep sedation is instituted for treatment of elevated ICP. If Deep sedation is needed to manage elevated ICP, then change administration instructions within analgesia and sedation order to reflect new COMFORT and RASS goals.
- Initial dosing of sedative continuous infusions:
  - Titrate sedative continuous infusions, including fentanyl, midazolam, and dexmedetomidine (be careful with dexmedetomidine in first 72 hours).

**Indications for ICP Monitoring**
The decision to monitor ICP is based on Glasgow Coma Score (GCS), CT scan findings, and clinical scenario at the discretion of the on-call neurosurgery attending.
- Strongly consider an ICP monitor in patients with GCS of eight (8) or less after initial resuscitation, especially if CT scan shows mass lesions (e.g. hematoma, edema), effaced basilar cisterns, or diffuse edema.
  - An ICP monitor may be placed in the setting of a borderline GCS when neurologic exam is unavailable for a prolonged period of time, e.g. emergent non-cranial surgery.
- For those going to operating room for removal of an intracranial mass (bleed), the need for monitoring will be assessed at surgery.
- The decision for or against the placement of an ICP monitoring device should be communicated by the neurosurgery attending to the trauma service and PICU attendings as well as their level of concern for anticipated ICP elevations and threshold for interventions (i.e. ICP, exam changes, EVD output).
• External ventricular drainage is preferred in cases when ventricles are deemed adequate without significant anatomical distortion, are enlarged or where CSF diversion is likely to be beneficial for ICP control.

• If GCS is marginal (9-13), and ICP monitor is not placed, follow exam with minimum necessary sedation/analgesia.

• GCS is assessed hourly by ICU nursing staff, with any decline in exam communicated to the PICU provider who will communicate with the neurosurgical services. Subacute development of elevated ICP with need for medical or surgical interventions is possible from ongoing brain swelling.

• If signs of herniation are present, consider giving hypertonic saline 3% (0.5 mEq/mL Na+) (5 mL/kg) or mannitol (1 gm/kg IV) or mild hyperventilation (ETCO2 32-35) while monitor is being placed.

THERAPEUTICS

Treatment of Elevated ICP

• Treatments are initiated for intracranial hypertension as defined by elevated ICP. Table 1 defines threshold values for treatment by age group. ICP units are mmHg (20 cm H2O = 14.7 mmHg).

• Treat if ICP is above stated values. Treat Cerebral perfusion pressure (CPP) only when ICP cannot be controlled.

Table 1: Age Appropriate Pressure Ranges

<table>
<thead>
<tr>
<th>Age</th>
<th>MAP (mmHg)</th>
<th>ICP (mmHg)</th>
<th>ICP Treatment Threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-23 months</td>
<td>50-70</td>
<td>Less than or equal to 15</td>
<td>Greater than or equal to 20</td>
</tr>
<tr>
<td>2-5 years</td>
<td>60-80</td>
<td>Less than or equal to 15</td>
<td>Greater than or equal to 20</td>
</tr>
<tr>
<td>6-8 years</td>
<td>65-85</td>
<td>Less than or equal to 20</td>
<td>Greater than or equal to 20</td>
</tr>
<tr>
<td>Greater than or equal to 9 years</td>
<td>70-95</td>
<td>Less than or equal to 20</td>
<td>Greater than or equal to 20</td>
</tr>
</tbody>
</table>

Mean Arterial Pressure (MAP)

• Elevate head of bed to 30 degrees – This is done in moderate to severe TBI patients.

• Check that cervical collar is loose enough to allow jugular venous return (able to easily slip a finger between collar and neck).

• Comfort sedation – Sedate as needed to a Richmond Agitation and Sedation Score (RASS) of -1. Short-acting agents are preferred. All intubated patients should receive comfort sedation.

• Cerebral spinal fluid (CSF) diversion – open external ventricular drain (EVD) if clamped and notify the PICU provider who will notify neurosurgery.

  o Consider placing an EVD or replacement of ICP monitor with EVD if ICP becomes refractory unless ventricles are slit-like or casted with blood

Hyperosmolar Therapy

• Hypertonic Saline 3% (0.5 mEq/mL Na+) is the first-line osmotic in any patient who is not fluid overloaded.

  o Administer a bolus of 5 mL/kg IV over 15 minutes for acutely elevated ICP.

  o Infuse 0.1 - 1 mL/kg/hour continuously for maintenance of ICP control.

• Check serum sodium and osmolality every 4 hours while actively administering hyperosmolar therapy.

  o If sodium is greater than 165, be cautious and carefully consider administration of hypertonic saline.

• If limitation of total fluid volume is required (eg. in a patient receiving large amounts of fluid from drips and antibiotics), 12% (2 mEq/mL Na+) or 23.4% (4 mEq/mL Na+) saline solution may be substituted for 3% (0.5 mEq/mL Na+).

<table>
<thead>
<tr>
<th>Hypertonic Saline %</th>
<th>Hypertonic Sodium Concentration</th>
<th>Recommended Dose</th>
<th>Max Dose Volume</th>
<th>Expected increase in serum sodium</th>
</tr>
</thead>
<tbody>
<tr>
<td>3%</td>
<td>0.5 mEq/mL</td>
<td>5 mL/kg</td>
<td>234 mL</td>
<td>5 mEq/mL</td>
</tr>
<tr>
<td>12%</td>
<td>2 mEq/mL</td>
<td>1 mL/kg</td>
<td>60 mL</td>
<td>5 mEq/mL</td>
</tr>
<tr>
<td>23.4%</td>
<td>4 mEq/mL</td>
<td>0.5 mL/kg</td>
<td>30 mL</td>
<td>5 mEq/mL</td>
</tr>
</tbody>
</table>
• Mannitol
  o Consider mannitol if:
    • Hypertonic saline is not immediately available.
    • Patient is fluid overloaded.
    • ICP does not respond to initial hypertonic saline (HTS) bolus.
    • Mannitol should be used with caution if serum OSM is greater than 340.
  o Dosing: [Refer to Formulary]
  o Check serum osmolality (OSM) and calculated OSM prior to repeat bolus after infusion. If OSM gap is greater than 10 mmol, would not administer more mannitol since it is still circulating.
  o Osmolality (OSM) = (2 × Na⁺) + (glucose ÷ 18) + (BUN ÷ 3); OSM gap = Serum OSM – Calculated OSM

Cerebral hypoperfusion
The below therapies are instituted in the following order when ICP cannot be controlled and CPP is low as defined by Table 1. They may also be considered when ICP is normal but mean arterial pressure (MAP) is low. Cerebral perfusion pressure (CPP) is calculated as follows: CPP=MAP-ICP.

  o Bolus IV fluid – Normal saline, colloid, or blood.
  o Repeat boluses to maintain euvolemia
  o Norepinephrine—Titrate to goal cerebral perfusion pressure (CPP)
  o Additional pressors as necessary—Titrate to goal cerebral perfusion pressure (CPP)

Sedation

Comfort sedation:
• Richmond Agitation and Sedation Score (RASS) less than or equal to –1 Comfort score 17-24
• With a goal of preserving a neurologic exam and safety for the patient

Deep Sedation:
• May be used concurrently with hyperosmolar therapy or prior to hyperosmolar therapy, according to provider discretion.
• Deep sedation for control of ICP refractory to osmotic therapy. Nursing maneuvers are minimized and neurologic exams should be minimized during deep sedation to minimize any stimulation to the patient.

Neuromuscular blockade
• Add neuromuscular blockade if ICP is refractory to sedation.
• Rocuronium – 1 mg/kg bolus or cisatracurium 1 to 4 mcg/kg/minute
• Titrate infusion to ICP control. Monitor paralysis with trains of four with maximal therapy being reached when there is either ICP control or an absence of a train of four twitches. Other neuromuscular blockers may be used if indicated.
• Institute EEG monitoring when neuromuscular blockade is ongoing.
• Sedation and neuromuscular blockade may acutely raise pCO₂ (and hence ICP) if patient has been over-breathing the ventilator prior to administration. End Tidal CO₂ (ETCO₂) monitoring diagnoses this and allows appropriate monitoring of ventilator changes.
• Evaluate responsiveness to sedation boluses given for ICP as additional sedation may not be beneficial if there are no clinical signs of responsiveness to additional boluses

Second-line ICP therapies
**Pentobarbital Coma**
- Consider in severe, non-lateralized, potentially salvageable cases.
- Initial bolus of 10 mg/kg bolus over 30 min (can use a smaller bolus of 3-5mg/kg or slower infusion rate if hypotension develops).
  - Follow the initial bolus with 5 mg/kg/hr of pentobarbital for 3 hours
  - Continue pentobarbital infusion at 1 mg/kg/hr
- Titrate to ICP effect and consider monitoring with continuous EEG monitoring with a target of 90% suppression (or a 1 second burst per 10 seconds of suppression) as a maximal therapy.
- Close blood pressure monitoring will be needed. Order pressors to bedside prior to administration of pentobarbital bolus.
- Monitor for pancreatitis (lipase every 3 days) and infection (daily blood cultures).

**Decompressive Craniectomy**
- PICU attending and neurosurgery attending discussion of indication for decompressive craniectomy:
  - Consider in lateralized cases or bifrontal craniectomy in non-lateralized cases with some likelihood of survival

**Order of ICP Therapy weaning**
- Normocapnia
- Barbiturate withdrawal as tolerated (ICP/ CPP)
- Paralytic withdrawal as tolerated (ICP/CPP)
- Sedation withdrawal as tolerated (Long-acting opiate/benzodiazepine as indicated)
- Normalize serum sodium and osmolarity

**SYSTEMIC MANAGEMENT OF PATIENTS WITH MODERATE/SEVERE BRAIN INJURY**

**Nutrition**
- Traumatic brain injury is associated with significant elevation in mean energy expenditure above predicted levels.
  - Adult data suggests that early feeding after TBI (in first five-seven days) is associated with lower mortality rates.
  - Institute enteral, parenteral, or combination nutrition within 48 hours after injury
  - Parenteral nutrition may be delayed up to one week in compromised patients
  - Nutrition consult to assist in determining optimal volume and content of feeds/TPN

**PICU Nutrition Guidelines:**
- PICU Enteral Nutrition Guideline
- PICU Parenteral Nutrition Guideline

**Venous Thromboembolism (VTE) prophylaxis and Treatment:**
Due to the complexity of the Moderate/Severe TBI population please use the following VTE prophylaxis recommendations. **Do not** use the standard VTE Prevention clinical pathway recommendations for these patients.

**Prophylaxis:**
For VTE prophylaxis in TBI there are special consideration please see the VTE prophylaxis algorithm

**Treatment:**
The risk: benefit ratio of pharmacologic treatment of a documented venous thromboses, regardless of location (superficial vs deep DVT), is poorly defined for TBI patients and management decisions should be multidisciplinary between the involved surgical, critical care, and hematology services.

- Any intracranial hemorrhage is a relative contraindication to treatment-dose anticoagulation
- Any intracranial foreign body (external ventricular drain (EVD), ICP monitor) should be considered a relative contraindication to treatment-dose anticoagulation given an increased risk of associated hemorrhage in the acute post traumatic period. Multidisciplinary discussion is highly recommended.

- If pharmacologic treatment is deemed necessary in a patient with intracranial hemorrhage, strong consideration should be given to the following approaches:
  - Use a standard heparin infusion, without loading dose.
  - Target lower heparin assay levels (0.2-0.3 U/mL) for 2-4 days before escalating to full treatment dose
  - Repeat brain imaging before escalating to full treatment doses of heparin and/or transitioning to enoxaparin.

Coagulopathy

- Correct coagulopathy, as clinically indicated, in the initial 48 hours following injury, particularly when intracranial hemorrhage is present or intracranial procedures may be necessary.

Rehabilitation

- Consult Physical Medicine & Rehabilitation (PM&R) for patients that have stabilized or have been hospitalized for greater than 5 days
- Consult PT/OT within 48 hours of admission for early passive range of motion, bracing & splinting, and out of bed when appropriate.
- Consult speech therapy when patient stabilized or have been hospitalized for greater than 5 days to assist with assessing swallowing abilities and communication even while intubated.
- Consult rehab neuropsychology when PM&R is consulted to assist with TBI education, coping with rehab process and adjustment to cognitive changes.
  - Colorado Springs consideration: If the patient is assessed by the on staff rehabilitation psychiatrist and it is determined that a neuropsychologist is needed, consult the Anschutz team to discuss treatment and/or transfer options

SPECIAL CONSIDERATIONS FOR SUSPECTED ABUSIVE HEAD TRAUMA

For Children less than 2.5 years of age

In children less than 2.5 years of age with concerns for or suspected abusive head trauma who:

- Present with seizures, apnea, sleepiness or irritability
- AND Have intracranial hemorrhage (subdural, subarachnoid, intraventricular or intraparenchymal hemorrhage) on initial imaging

Due to 1) the difficulty assessing mental status in young children, 2) unreliability of GCS in stratifying the severity of injury and 3) an increased risk of seizures (including clinical and subclinical seizures that may require ICU care) children meeting the above criteria should be:

- Admitted to the PICU for 24-48 hours
- Placed on continuous EEG for 72 hours (including after transfer from the ICU if less than 72 hours)

For all children with suspected abusive head trauma

EEG
Consider prolonged EEG monitoring (48-72 hours), since the majority of patients with abusive head trauma will have subclinical seizures which may be present on admission or delayed 24-72 hours.

**MRI Imaging**

Cases of suspected abusive head trauma may be of unknown timing and mechanism. As a result, they warrant aggressive monitoring and oftentimes further imaging. Definitive MRI brain imaging should be performed no earlier than 48 hours after admission and preferably 72 hours after admission, but no later than 7 days following admission. The order should be for: “MRI brain with and without contrast, with venography”. Also request “MRI cervical spine without contrast.” Additional MRIs may be obtained outside the 72 hour-7 day window to assist with medical management, as needed.
## Appendix A: Overview of Richmond Agitation and Sedation Score (RASS)

<table>
<thead>
<tr>
<th>Score</th>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>+4</td>
<td>Combative</td>
<td>Overtly combative or violent; immediate danger to staff</td>
</tr>
<tr>
<td>+3</td>
<td>Very agitated</td>
<td>Pulls on or removes tube(s) or catheter(s) or has aggressive behavior toward staff</td>
</tr>
<tr>
<td>+2</td>
<td>Agitated</td>
<td>Frequent non-purposeful movement or patient-ventilator dyssynchrony</td>
</tr>
<tr>
<td>+1</td>
<td>Restless</td>
<td>Anxious or apprehensive bust movements not aggressive or vigorous</td>
</tr>
<tr>
<td>0</td>
<td>Alert and calm</td>
<td></td>
</tr>
<tr>
<td>-1</td>
<td>Drowsy</td>
<td>Not fully alert, but has sustained (more than 10 seconds) awakening, with eye contact, to voice</td>
</tr>
<tr>
<td>-2</td>
<td>Light sedation</td>
<td>Briefly (less than 10 seconds) awakens with eye contact to voice</td>
</tr>
<tr>
<td>-3</td>
<td>Moderate sedation</td>
<td>Any movement (but no eye contact) to voice</td>
</tr>
<tr>
<td>-4</td>
<td>Deep sedation</td>
<td>No response to voice, but any movement to physical stimulation</td>
</tr>
<tr>
<td>-5</td>
<td>Unarousable</td>
<td>No response to voice or physical stimulation</td>
</tr>
</tbody>
</table>
Appendix B: VTE Prophylaxis for TBI

TBI Patient in the PICU

Mechanical Prophylaxis

Patient Age?

Age less than 12 years

Any of the following:
- Known clotting disorder?
- Personal history venous thromboembolism (VTE)? OR
- Strong family history VTE?

No

Mechanical Prophylaxis only

Age greater than or equal to 12 years

Assess Bleeding Risk

Risk Factors:
- Craniotomy
- EVD/ICP monitor in place
- Moderate/large (greater than 5 mm) subdural, epidural, or IVH
- Moderate/large (greater than 1 cm) contusion
- INR greater than 1.5
- Platelets less than 100K
- Other site of bleeding (liver, spleen, pelvis)

High Bleeding risk? (any risk factors present)

Yes

Reassess 24 hours after injury

Clinically stable? Repeat imaging (if obtained) stable?

Yes

Complete CHCO VTE risk assessment

No

High VTE Risk

Enoxaparin Prophylaxis

No

Moderate/Low VTE Risk

Mechanical Prophylaxis only

No

Reassess 72 hours after injury

Clinically stable? Repeat imaging (if obtained) stable?

Yes

No

Notes:
- For TBI patients with known clotting disorders, personal history of venous thromboembolism (VTE), or strong family history of VTE, consult Hematology for discussion of VTE prophylaxis and/or treatment.
- Reassessment for bleeding risk should occur at 24 and 72 hours after injury and/or instrumentation (including EVD/ICP monitor placement and craniotomies), whichever is most recent.
- For reassessment of patients at 24 and 72 hours, repeat brain imaging should be considered but is not required to start VTE prophylaxis.
- For patients with low bleeding risk and high VTE risk, start enoxaparin prophylaxis per CHCO VTE guideline.
REFERENCES


2. Reiter PD, Pietras M, Dobyns EL. Prolonged dexmedetomidine infusions in critically ill infants and children. Indian Pediatr. 2009 Sep;46(9):767-73


CLINICAL IMPROVEMENT TEAM MEMBERS

Craig Press, MD, PhD | Neurology
Tell Bennett, MD, MS | Critical Care
Brent O’Neill, MD | Neurosurgery
Ricka Messer, MD, PhD | Neurology
Amy Clevenger, MD, PhD | Critical Care
Steven Moulton, MD | Trauma
Todd Hankinson, MD | Neurosurgery
Patrick Mahar, MD | Emergency Medicine

Todd Carpenter, MD | Critical Care
Matthew Mayer, MD | Physical Medicine & Rehabilitation
Brian Branchford, MD | Hematology
John Recicar, RN, MBA | Trauma
Joni Mackenzie, PNP | Emergency Medicine
Beth Wathen, MSN, APRN, CCRN | Critical Care
Pam Reiter, PharmD | Clinical Pharmacist

APPROVED BY

Clinical Pathways and Measures Committee – March 13, 2018; Edits completed & approved May 2021
Pharmacy & Therapeutics Committee – March 1, 2018; Edits completed & approved May 2021

MANUAL/DEPARTMENT | Clinical Pathways/Quality
ORIGINATION DATE | March 13, 2018
LAST DATE OF REVIEW OR REVISION | May 2021; Edits completed & approved
COLORADO SPRINGS REVIEW BY | Michael DiStefano, MD
Chief Medical Officer, Colorado Springs
APPROVED BY | Lalit Bajaj, MD, MPH
Medical Director, Clinical Effectiveness

REVIEW | REVISION SCHEDULE

Scheduled for full review on date here March 13, 2022.

Clinical pathways are intended for informational purposes only. They are current at the date of publication and are reviewed on a regular basis to align with the best available evidence. Some information and links may not be available to external viewers. External viewers are encouraged to consult other available sources if needed to confirm and supplement the content presented in the clinical pathways. Clinical pathways are not intended to take the place of a physician’s or other health care provider’s advice, and is not intended to diagnose, treat, cure or prevent any disease or other medical condition. The information should not be used in place of a visit, call, consultation or advice of a physician or other health care provider. Furthermore, the information is provided for use solely at your own risk. CHCO accepts no liability for the content, or for the consequences of any actions taken on the basis of the information provided. The information provided to you and the actions taken thereon are provided on an “as is” basis without any warranty of any kind, express or implied, from CHCO. CHCO declares no affiliation, sponsorship, nor any partnerships with any mentioned organization.
Discrimination is Against the Law. Children’s Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Children’s Hospital Colorado does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Children’s Hospital Colorado provides free aids and services to people with disabilities to communicate effectively with us, such as: Qualified sign language interpreters, written information in other formats (large print, audio, accessible electronic formats, other formats). Children’s Hospital Colorado provides free language services to people whose primary language is not English, such as: Qualified interpreters, information written in other languages.

If you need these services, contact the Medical Interpreters Department at 720-777-9800.

If you believe that Children’s Hospital Colorado has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Corporate Compliance Officer, 13123 E. 10th Avenue, B450, Aurora, Colorado 80045, Phone: 720 777 1234, Fax: 720 777 7257, corporatecompliance@childrenscolorado.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Corporate Compliance Officer is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at portal.hhs.gov/corporal/lobbyyst, by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHQ Building Washington, D.C. 20201 1 800 368 1019, 800 337 7607 (TDD) Complaint forms are available at www.hhs.gov/ocr/office/file/index.html.

Children’s Hospital Colorado complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.

ATENÇÃO: se habla español, bene a su disposición servicios gratuitos de asistencia linguística. Llame al 1-720-777-9800.


注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電1-720-777-9800。

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-720-777-9800.

ПРЕДУПРЕЖДЕНИЕ: Если вы говорите на испанском языке, вам предоставляются бесплатные услуги перевода. Звоните 1-720-777-9800.

BANGALI: ক্লিনিকাল পাথওয়ায় মানুষের মূল্যমন্ত্র নিরপেক্ষ এবং সমস্ত মানুষের মতো সম্মত। 1-720-777-9800 (HINDI: 1-720-777-9800)